Anti-Cytokeratin 5 + 6 antibody [D5/16 B4] (ab17133)
Key features and details
- Mouse monoclonal [D5/16 B4] to Cytokeratin 5 + 6
- Suitable for: IHC-P
- Reacts with: Human
- Isotype: IgG1
Overview
-
Product name
Anti-Cytokeratin 5 + 6 antibody [D5/16 B4] -
Description
Mouse monoclonal [D5/16 B4] to Cytokeratin 5 + 6 -
Host species
Mouse -
Tested applications
Suitable for: IHC-Pmore details -
Species reactivity
Reacts with: Human -
Immunogen
Full length native protein (purified) corresponding to Human Cytokeratin 5 + 6.
-
Positive control
- IHC-P: Human tonsil tissue.
-
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Store at -20°C or -80°C. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.3
Preservative: 0.05% Sodium azide
Constituent: 1% BSA -
Concentration information loading...
-
Purity
Protein G purified -
Clonality
Monoclonal -
Clone number
D5/16 B4 -
Isotype
IgG1 -
Light chain type
kappa -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab17133 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
IHC-P | (2) |
1/25 - 1/50.
Pretreat tissue with citrate buffer pH 6. Incubate with primary antibody for 30 minutes at room temperature. |
Notes |
---|
IHC-P
1/25 - 1/50. Pretreat tissue with citrate buffer pH 6. Incubate with primary antibody for 30 minutes at room temperature. |
Target
-
Relevance
Cytokeratin 5 (58 kD) is a high molecular weight, basic type of cytokeratin expressed in basal, the intermediate and the superficial cell layers of stratified epithelia as well as transitional epithelia, complex epithelia and in mesothelial cells and mesothelioma. Cytokeratin 6 (56 kD) is also a high molecular weight, basic type cytokeratin expressed by proliferating squamous epithelium often paired with Cytokeratin 16. -
Cellular localization
Cytoplasmic -
Database links
- Entrez Gene: 3852 Human
- Entrez Gene: 3853 Human
- Entrez Gene: 3854 Human
- Omim: 148040 Human
- SwissProt: P02538 Human
- SwissProt: P04259 Human
- SwissProt: P13647 Human
-
Alternative names
- Cytokeratin 5 antibody
- Cytokeratin 6A antibody
- Cytokeratin 6B antibody
see all
Images
Datasheets and documents
-
SDS download
-
Datasheet download
References (12)
ab17133 has been referenced in 12 publications.
- Xu Y et al. Immunosuppressive tumor-associated macrophages expressing interlukin-10 conferred poor prognosis and therapeutic vulnerability in patients with muscle-invasive bladder cancer. J Immunother Cancer 10:N/A (2022). PubMed: 35338085
- Ding RB et al. Molecular landscape and subtype-specific therapeutic response of nasopharyngeal carcinoma revealed by integrative pharmacogenomics. Nat Commun 12:3046 (2021). PubMed: 34031426
- Al-Khalaf HH et al. Senescent Breast Luminal Cells Promote Carcinogenesis through Interleukin-8-Dependent Activation of Stromal Fibroblasts. Mol Cell Biol 39:N/A (2019). PubMed: 30397077
- Vahidnezhad H et al. Biallelic KRT5 mutations in autosomal recessive epidermolysis bullosa simplex, including a complete human keratin 5 "knock-out". Matrix Biol 83:48-59 (2019). PubMed: 31302245
- Ota T et al. Validity of using immunohistochemistry to predict treatment outcome in patients with non-small cell lung cancer not otherwise specified. J Cancer Res Clin Oncol 145:2495-2506 (2019). PubMed: 31494736